Open AccessPerspectives of incretin mimetics in cardiovascular diseases
Author(s) -
João Felipe Rito Cardoso,
Célia Cohen,
Fernanda Medeiros,
Fabiano Marcel Serfaty,
Mário Fritsch Neves
Publication year - 2021
Publication title -
brazilian journal of health and biomedical sciences
Language(s) - English
Resource type - Journals
ISSN - 2674-8207
DOI - 10.12957/bjhbs.2021.59746
Subject(s) - incretin , medicine , type 2 diabetes , diabetes mellitus , hypoglycemia , type 2 diabetes mellitus , intensive care medicine , insulin resistance , albuminuria , bioinformatics , endocrinology , biology
Type 2 Diabetes (DM2) is a chronic conditionassociated with an increased risk of cardiovascular diseases,neuropathies, nephropathies and eye diseases. Incretins (GIPand GLP-1) are hormones important to insulin secretion, andtheir actions are compromised in DM2 patients. Objectives:This review considers the opportunities and challenges ofusing incretin mimetics in the treatment of DM2. Methods:Bibliographic review referring to the period from 2000 to2020, in electronic databases such as Scielo, Lilacs, PubMed,Web of Science. Results: Incretins stimulate insulin secretionby the pancreas in response to nutrient intake, with a lowerpotential to cause hypoglycemia. In addition, they have acardioprotective role, reducing blood pressure, improvingendothelial and myocardial function, and their use has beenassociated with a reduction in the risk of cardiovascularevents, including cardiovascular mortality. Clinical trialswith GLP-1R agonists (GLP-1RA) reduced albuminuria, increasednatriuresis, and decreased oxidative stress. In addition,treatment with incretin mimetics reduced the occurrence ofthe main cardiovascular outcomes related to atherosclerosis,promoted weight loss and improved lipid profile. Conclusion:Studies show the important role of incretin mimetics in thepathophysiology and treatment of DM2, with significanteffects in the cardiovascular system. However, its use must beevaluated in relation to its safety and to in which individualsthe benefits outweigh the risks associated with the treatment.Thus, its clinical relevance depends on studies with long-termfollow-up of patients, with analysis of its impact on mortalityand on the development of micro and macrovascularcomplications.